Paul Wick has managed the Columbia Seligman Technology and Innovation Fund since 1990, obtaining notable results. By outperforming his peers, Wick’s strategy and decisions in tech investment have set him apart. His journey began with a brief introduction to tech investing before taking over the fund.
Performance Highlights
Wick’s fund performance is impressive. In the past 15 years, the fund has outdone 93% of U.S. technology funds. According to Morningstar data, a $10,000 investment a decade ago would now be valued at $109,000. Even amid an AI-driven market surge, Wick’s fund outperformed, rising 55% in 2026 compared to the 13% increase in the S&P 500.
Keys to Success
Wick identifies several factors contributing to his success:
- Team Continuity: Most team members have worked with him for over a decade, providing stability.
- Location and Scale: Located in Menlo Park, the heart of Silicon Valley, offers significant access to tech companies.
- Expertise: The team includes experienced semiconductor analysts with industry backgrounds.
- Strategic Selection: The fund focuses on companies with competitive moats, strong management, and attractive valuations.
Wick emphasizes identifying undervalued companies, particularly those neglected by the market. The fund’s focus has included AI-related capex beneficiaries, but Wick has diversified recently into software, internet, and cybersecurity stocks.
Top Holdings
As of September 30, the fund’s top holdings were:
- Bloom Energy (9.48%)
- Lam Research (5.38%)
- Nvidia (4.79%)
- Broadcom (4.78%)
- Marvell Technology (3.41%)
- Alphabet (3.3%)
- Microsoft (3.02%)
- Apple (2.92%)
- GoDaddy (2.68%)
- Western Digital (2.32%)
About Paul Wick
Beyond investing, Wick enjoys golf, tennis, scuba diving, and skiing. His travels have taken him to various diving spots worldwide, from New Jersey to the Red Sea and Fiji.
He also appreciates fine wine, recalling a memorable 25th anniversary celebration for the hedge fund. His favorite vacation spot is Kona on Hawaii’s Big Island.
One standout career moment involved a short position in the biotech company Allakos, which resulted in significant gains when the company’s trials failed.
Paul Wick continues to navigate the evolving landscape of technology investment with experienced insight and strategy.
Leave a Reply